From €300EUR$351USD£264GBP
- Report
- February 2023
- 96 Pages
Global
From €1800EUR$2,105USD£1,583GBP
From €300EUR$351USD£264GBP
From €300EUR$351USD£264GBP
From €300EUR$351USD£264GBP
- Report
- August 2023
- 267 Pages
Global
From €2150EUR$2,514USD£1,891GBP
- Report
- June 2022
- 115 Pages
Global
From €1050EUR$1,228USD£924GBP
- Report
- May 2022
- 50 Pages
Global
From €500EUR$585USD£440GBP
- Report
- May 2022
- 32 Pages
Global
From €400EUR$468USD£352GBP
- Report
- October 2021
- 433 Pages
Global
From €2250EUR$2,631USD£1,979GBP
- Report
- April 2024
- 270 Pages
Global
From €4580EUR$5,000USD£3,893GBP
- Report
- February 2022
- 272 Pages
Global
From €5496EUR$6,000USD£4,671GBP
- Report
- December 2019
- 59 Pages
Global
From €3664EUR$4,000USD£3,114GBP
- Report
- February 2024
- 50 Pages
Global
From €2199EUR$2,400USD£1,869GBP
- Report
- December 2023
- 220 Pages
Global
From €3023EUR$3,300USD£2,569GBP
- Report
- October 2023
- 420 Pages
Global
From €2657EUR$2,900USD£2,258GBP
- Report
- March 2023
- 300 Pages
Global
From €2565EUR$2,800USD£2,180GBP
- Report
- June 2022
- 1500 Pages
Global
From €3573EUR$3,900USD£3,036GBP
- Drug Pipelines
- May 2022
- 400 Pages
Global
From €2748EUR$3,000USD£2,336GBP
- Report
- February 2022
- 360 Pages
United States
From €3298EUR$3,600USD£2,803GBP

T Cell Therapies are a type of biotechnology that involves the use of a patient's own T cells to treat diseases. T cells are a type of white blood cell that play a key role in the body's immune system. T Cell Therapies involve the extraction of T cells from a patient, engineering them to recognize and attack specific targets, and then reintroducing them into the patient's body. This type of therapy has been used to treat a variety of cancers, including leukemia, lymphoma, and multiple myeloma. It has also been used to treat autoimmune diseases, such as rheumatoid arthritis and Crohn's disease.
T Cell Therapies are a rapidly growing field of biotechnology, with many companies investing in research and development. Companies such as Kite Pharma, Juno Therapeutics, and Novartis are leading the way in developing and commercializing T Cell Therapies. Other companies, such as Gilead Sciences, Celgene, and Regeneron, are also investing in the field. Show Less Read more